Monopar Therapeutics (NASDAQ:MNPR) Shares Down 5.7% – What’s Next?

Monopar Therapeutics Inc. (NASDAQ:MNPR)’s stock price was down 5.7% during mid-day trading on Monday. The stock traded as low as $64.95 and last traded at $66.28. 218,899 shares were traded during trading, an increase of 57% from the average daily volume of 139,654 shares. The stock had previously closed at $70.32.

Analyst Ratings Changes

A number of research analysts have recently commented on MNPR shares. HC Wainwright upped their price objective on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a research report on Wednesday, July 22nd. Wall Street Zen downgraded Monopar Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 10th. Cantor Fitzgerald lowered Monopar Therapeutics from an “overweight” rating to a “neutral” rating and boosted their price target for the company from $109.00 to $119.00 in a research note on Thursday, August 13th. Zacks Research cut Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 13th. Finally, Barclays reaffirmed an “overweight” rating and issued a $145.00 price target (up from $128.00) on shares of Monopar Therapeutics in a report on Friday, September 11th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $122.00.

Monopar Therapeutics Trading Down 5.7%

The stock has a market cap of $444.74 million, a P/E ratio of -30.54 and a beta of 1.50. The company’s fifty day simple moving average is $90.25 and its 200-day simple moving average is $77.38.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.02. As a group, analysts expect that Monopar Therapeutics Inc. will post -2.98 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Raymond Anderson sold 3,142 shares of the stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $111.77, for a total transaction of $351,181.34. Following the sale, the director directly owned 23,751 shares in the company, valued at $2,654,649.27. This represents a 11.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher M. Starr sold 8,400 shares of the firm’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $78.50, for a total transaction of $659,400.00. Following the completion of the sale, the director owned 5,173 shares of the company’s stock, valued at $406,080.50. The trade was a 61.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 44,688 shares of company stock worth $4,023,094 over the last 90 days. 9.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Monopar Therapeutics

Several institutional investors have recently modified their holdings of MNPR. Bank of New York Mellon Corp acquired a new stake in shares of Monopar Therapeutics during the second quarter worth $7,124,000. Bank of America Corp DE lifted its position in Monopar Therapeutics by 838.2% during the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after buying an additional 53,336 shares in the last quarter. ADAR1 Capital Management LLC boosted its holdings in shares of Monopar Therapeutics by 13.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after buying an additional 30,370 shares during the last quarter. The Manufacturers Life Insurance Company bought a new position in Monopar Therapeutics during the first quarter worth about $250,000. Finally, Siren L.L.C. boosted its position in Monopar Therapeutics by 27.2% during the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after purchasing an additional 57,820 shares during the period. Institutional investors and hedge funds own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing investigational therapies for cancer. The company’s research programs are centered on radiopharmaceuticals and oncology treatments intended to improve the diagnosis and treatment of serious malignancies.

Monopar’s pipeline includes MNPR-101-Zr, a zirconium-89-labeled antibody fragment being developed as a positron emission tomography imaging agent targeting the urokinase plasminogen activator receptor, or uPAR.